Hamburg, 15.05.2026 – Although the infectious disease Lassa fever can be fatal, there is a lack of treatment options with proven efficacy. Researchers at the Bernhard Nocht Institute for Tropical Medicine (BNITM) and the University Medical Center Hamburg-Eppendorf (UKE) have led the first randomised clinical trial with the new drug candidate favipiravir. The promising results have been published in the journal Nature Medicine.